Suppr超能文献

肠道微生物组与心血管疾病:现有知识与临床潜能。

The gut microbiome and cardiovascular disease: current knowledge and clinical potential.

机构信息

Medical School, University of Western Australia, Perth, Western Australia, Australia.

Department of Advanced Clinical and Translational Cardiovascular Imaging, Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia.

出版信息

Am J Physiol Heart Circ Physiol. 2019 Nov 1;317(5):H923-H938. doi: 10.1152/ajpheart.00376.2019. Epub 2019 Aug 30.

Abstract

Cardiovascular disease (CVD) is the leading cause of death worldwide. The human body is populated by a diverse community of microbes, dominated by bacteria, but also including viruses and fungi. The largest and most complex of these communities is located in the gastrointestinal system and, with its associated genome, is known as the gut microbiome. Gut microbiome perturbations and related dysbiosis have been implicated in the progression and pathogenesis of CVD, including atherosclerosis, hypertension, and heart failure. Although there have been advances in the characterization and analysis of the gut microbiota and associated bacterial metabolites, the exact mechanisms through which they exert their action are not well understood. This review will focus on the role of the gut microbiome and associated functional components in the development and progression of atherosclerosis. Potential treatments to alter the gut microbiome to prevent or treat atherosclerosis and CVD are also discussed.

摘要

心血管疾病 (CVD) 是全球范围内的主要死亡原因。人体中存在着一个多样化的微生物群落,以细菌为主,但也包括病毒和真菌。这些微生物群落中最大和最复杂的群落位于胃肠道系统中,其相关基因组被称为肠道微生物组。肠道微生物组的扰动和相关的生态失调与 CVD 的进展和发病机制有关,包括动脉粥样硬化、高血压和心力衰竭。尽管在肠道微生物组及其相关细菌代谢物的特征描述和分析方面已经取得了进展,但它们发挥作用的确切机制尚不清楚。本综述将重点关注肠道微生物组及其相关功能成分在动脉粥样硬化发展和进展中的作用。还讨论了改变肠道微生物组以预防或治疗动脉粥样硬化和 CVD 的潜在治疗方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验